Observational studyClinical research in cardiology : official journal of the German Cardiac Society2014
Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold.
Observational study in Clinical research in cardiology : official journal of the German Cardiac Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- The Safety and Efficacy of Absorb Bioresorbable Vascular Scaffold: A Systematic Review.Clinical cardiology · 2016Pooled it
- Bioresorbable Vascular Scaffold Korean Expert Panel Report.Korean circulation journal · 2017Review
- Are acute coronary syndromes an ideal scenario for bioresorbable vascular scaffold implantation?Journal of thoracic disease · 2017Review
- Contemporary management of ST-segment elevation myocardial infarction.Internal and emergency medicine · 2016Review
- Bioresorbable vascular scaffolds - basic concepts and clinical outcome.Nature reviews. Cardiology · 2016Review
- Bioresorbable vascular scaffolds-time to vanish?Journal of thoracic disease · 2016Article
- Safety of percutaneous coronary intervention in patients with acute ischemic stroke/transient ischemic attack and acute coronary syndrome.Clinical research in cardiology : official journal of the German Cardiac Society · 2016Article
- Bioresorbable vascular scaffolds technology: current use and future developments.Medical devices (Auckland, N.Z.) · 2016Review
- A potential life-threatening complication after implantation of a bioresorbable scaffold for coronary stenting within a mechanically stressed region.Clinical research in cardiology : official journal of the German Cardiac Society · 2015Article
- Current status of clinically available bioresorbable scaffolds in percutaneous coronary interventions.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2015Article
- Feasibility of second-generation bioresorbable vascular scaffold implantation in complex anatomical and clinical scenarios.Clinical research in cardiology : official journal of the German Cardiac Society · 2015Article
- Bioresorbable vascular scaffold implantation in acute coronary syndromes: clinical evidence, tips and tricks.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2015Review
- Acute revascularization in ST-segment-elevation myocardial infarction.Current atherosclerosis reports · 2014Review
- Successful ablation of a bioresorbable polymeric vascular scaffold by rotational atherectomy.Clinical research in cardiology : official journal of the German Cardiac Society · 2014Article
- Safety and efficacy of different stent types for the endovascular therapy of extracranial vertebral artery disease.Clinical research in cardiology : official journal of the German Cardiac Society · 2014Article
- The Bioresorbable Stent in Perspective-How Much of an Advance is It?Interventional cardiology (London, England) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate safety and efficacy of the everolimus-eluting bioresorbable scaffold (BVS) in patients with ST-segment elevation myocardial infarction (STEMI).
backgroundAccording to the current guidelines, drug-eluting stents are the treatment of choice in patients with STEMI. BVS represents a new technology capable to restore the native vessel vasomotion and potentially avoiding long-term limitations such as stent thrombosis.
methodsFrom October 2012 to May 2013, patients with evidence of STEMI eligible for BVS implantation were included in this study. Exclusion criteria were not defined.
resultsA total of 25 patients, respectively 31 lesions, were treated. Procedural success was achieved in 97%. Two major adverse cardiac events occurred during hospitalization and follow-up: one patient with cardiogenic shock at the index procedure subsequently died. One patient suffered from instable angina with need for interventional revascularization of a previously untreated vessel. One target vessel failure as a consequence of an intra-procedural dissection was seen. However, no target lesion failure was noted. During 132.7 ± 68.7 days of follow-up none of the patients died.
conclusionOur findings suggest that implantation of BVS in STEMI patients is feasible in this small cohort of highly selected patients. Further evaluation in randomized-controlled trials is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.